Related Experiment Video
Updated: Mar 10, 2026

05:29
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
3.2K
S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Cancer Cell
|December 14, 2016
Abstract:
A recent study reports a novel small molecule inhibitor of MCL-1 with efficacy in killing MCL-1-dependent cancer cells in vitro and in vivo. With the advent of S63845, the targeting of BCL-2, BCL-XL, and MCL-1 is now possible in vivo, but optimal clinical use is yet to be determined.

